Hugel, a global total medical aesthetics company, posted its highest-ever first-quarter performance, fueled by robust sales across all product lines.
The company announced on May 8 that its consolidated revenue for the first quarter of 2025 reached KRW 89.8 billion, with operating profit at KRW 39 billion and net profit at KRW 30.9 billion. Compared to the same period last year, these figures represent increases of 20.9%, 62.6%, and 35.9%, respectively.
The robust earnings growth was driven by balanced gains across all product portfolios.
The company’s botulinum toxin Botulax, globally branded as Letybo, logged KRW40.7 billion in quarterly net sales, up 18.8% on-year, and made up 45% of the company’s total net sales in the January-March period. The toxin’s net sales showed the highest growth in the Asia-Pacific market, which includes China, Australia and Taiwan, with a 54% increase on-year.
Hyaluronic acid fillers such as THE CHAEUM and BYRYZN Skin Booster HA posted KRW34.4 billion in the first quarter net sales, up 17.7% on-year. The dermal fillers showed strong sales performance in Asia-Pacific, the Americas, and Europe as well as in South Korea.
Cosmetics achieved KRW13.2 billion in net sales for the first quarter with a notable 39.3% increase on-year. Derma cosmetics brand WELLAGE and high-end skincare brand BYRYZN BR continue to expand their customer reach by launching new products and diversifying local and global distribution channels.
“The first-quarter earnings broke records again with all products’ robust growth across the world. We will strive to solidify our global position through key momentum drivers such as additional shipments to the US and entry into the Middle East in the second quarter,” said a Hugel official.
